Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-05-08
2007-05-08
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S141100, C424S158100, C530S387100, C530S388100, C530S388200, C530S388230
Reexamination Certificate
active
08349479
ABSTRACT:
The present invention provides a method for treating or arresting the progress of pathologies characterized by an accumulation of extracellular matrix components by providing an agent to suppress the activity of transforming growth factor β (TGF-β) a peptide growth factor which is anabolic and leads to fibrosis and angiogenesis. In one embodiment, such agent is anti-TGF-β antibody. Pathologies which can be so treated include, but are not limited to, glomerulonephritis, adult respiratory distress syndrome and cirrhosis of the liver. The invention further provides a method for the diagnosis of pathologies, or incipient pathologies, which are characterized by the accumulation of extracellular matrix components in tissues by determining the levels of TGF-β in the tissues, a high level being indicative of such pathologies.
REFERENCES:
patent: 5571714 (1996-11-01), Dasch et al.
patent: 5583103 (1996-12-01), Ruoslahti et al.
patent: 5772998 (1998-06-01), Dasch et al.
patent: 5783185 (1998-07-01), Dasch et al.
patent: 5824655 (1998-10-01), Border
patent: 282317 (1988-09-01), None
patent: WO88/03151 (1988-05-01), None
Raghu et al. Am Rev Respir Dis 131: 281-289 (1985).
Border et al. J Clin Invest. 90: 1-7 (1997).
Border et al. NEJM 331: 1286-1292 (1994).
Giri et al. Thorax 48: 959-966 (1993).
Wahl et al. J. Exp. Med. 177: 225-230 (1993).
Border et al. Kidney Intl. 35(1) 341 (1989).
Mackay et al J. Clin. Investig. 83: 1160, 1989.
Connor et al. J. Clin. Investig. 83: 1661, 1989.
Bassols D. B. C. 263(6): 3039, 1988.
Flanders et al Biochem 27: 739, 1988.
Bassols et al., J. Biol. Chem. 263 (6): 3039-3045 (1988).
Harper et al., Kidney International. 26: 875-880 (1984).
Flanders et al., Biochemistry 27: 739-746 (1988).
Webster's Ninth New Collegiate Dictionary, Merriam-Webster Inc., Springfield, MA, 1990, p. 1237.
Ignotz, R.A. and Massague, J., Tranforming Growth Factor-β Stimulates the Expression of Fibronectin and Collagen and Their Incorporation into the Extracellular Matrix,J. Biol. Chem.261:4337-4345 (1986).
Roberts et al., Transforming Growth Factor Type β: Rapid Induction of Fibrosis and Angiogenesis In Vivo and Stimulation of Collagen Formation In Vitro,Proc. Natl. Acad. Sci. USA83:4167-4171 (1986).
Bassols, A. and Massague, J., Transforming Growth Factor β Regulates the Expression and Structure of Extracellular Matrix Chondroitin/Dermatan Sulfate Proteoglycans,J. Biol. Chem.263:3039-3045 (1988).
Border et al., Transforming Growth Factor β (TGFB) Uniquely Regulates Production and Structure of Glomerular Extracellular Matrix Proteoglycans,Am. Soc. Nephrol.Abstract 1287 (1988).
Flanders et al., Antibodies to Peptide Determinants in Transforming Growth Factor β and Their Applications,Biochemistry27:739-746 (1988).
MacKay et al., Transforming Growth Factor-β,J. Clin. Investigation, Inc.83:1160-1167 (1989).
Connor et al., Correlation of Fibrosis and Transforming Growth Factor-β Type 2 Levels in the Eye,J. Clin. Invest.83:1661-1666 (1989).
Chen et al., Transforming Growth Factor Type β Specifically Stimulates Synthesis of Proteoglycan in Human Adult Arterial Smooth Muscle Cells,Proc. Natl. Acad. Sci. USA84:5287-5291 (1987).
Harper et al.,Kidney International26:875-880 (1984).
Gressner, A.M., “Liver fibrosis: perspectives in pathobiochemical research and clinical outlook”Eur. J. Clin. Chem. Clin. Biochem.29 (5) :293-311 (1991).
Fausto et al., “Effects of TGF-betas in the liver: cell proliferation and fibrogenesis”Ciba Found. Symp.157:165-74 (1991).
Limper and Roman, “A versatile matrix protein with roles in thoracic development, repair and infection”Chest101(6) :1663-73 (1992).
Lissoos and Davis, “Pathogenesis of Hepatic Fibrosis and the Role of Cytokines”J. Clin. Gastroenterol.15(1) :64-68 (1992).
Border et al., “Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease”Nature360:361-364 (1992).
Roberts, Anita B. et al. “Transforming Growth Factor Type β: Rapid Induction of Fibrosis and Angiogenesis in vivo and Stimulation of Collagen Formation in vitro.” Proc. Natl. Acad. Sci. U.S.A. 83:4167-4171 (1986).
Mustoe, Thomas A. et al. “Acceleratied Healing of Incisional Wounds in Rats Induced by Transforming Growth Factor-β.” Science 237:233-1333-1336 (1987).
Quaglino, Daniela Jr. et al. “Transforming Growth Factor-Beta Stimulates Wound Healing and Modulates Extracellular Matrix Gene Expression in Pig Skin: Incisional Wound Model.” J. Invest. Derm. 97:34-42 (1991).
Quaglino, Daniela Jr. et al. “Transforming Growth Factor-β Stimulates Wound Healing and Modulates Extracellular Matrix Gene Expression in Pig Skin.” Lab. Invest. 63:307-319 (1990).
Sporn, Michael B. et al. “Some Recent Advances in the Chemistry and Biology of Transforming Growth Factor-Beta.” J. Cell Biol. 105:1039-1045 (1987).
Border, Wayne A. et al. “Role of TGF-β1 in Experimental Glomerulonephritis.” Ciba Foundation Symposium 157:178-193 (1991).
Castilla, Alberto et al. “Transforming Growth Factors β1 and α in Chronic Liver Disease.” New England J. Med. 324:933-940 (1991).
Border, Wayne A. and Ruoslahti, Erkki “Transforming Growth Factor-β in Disease: The Dark Side of Tissue Repair.” J. Clin. Invest. 90:1-6 (1992).
Okuda, Seiya et al. “Elevated Expression of Transforming Growth Factorβ and Proteoglycan Production in Experimental Glomerulonephritis.” J. Clin. Invest. 86:453-462 (1990).
Border, Wayne A. and Ruoslahti, Erkki “Transforming Growth Factor-β in Disease: The Dark Side of Tissue Repair.”J. Clin. Invest.90:1-6 (1992).
Sheehan, Dezna C. and Hrapchak, Barbara B. “Carbohydrates.”Theory and practice of Histotechnology.pp. 159-189 Battelle Press, Columbus (1980).
Border et al., “Transforming Growth Factor β (TGFB) Uniquely Regulates Production and Structure of Glomerular Extracellular Matrix Proteoglycans”,Kidney Intl.35(1) :341 (1989).
Border Wayne A.
Ruoslahti Erkki I.
Gambel Phillip
La Jolla Cancer Research Foundation
McDermott Will & Emery LLP
LandOfFree
Methods of decreasing the accumulation of extracellular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of decreasing the accumulation of extracellular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of decreasing the accumulation of extracellular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3731434